Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

December 2025

Efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis: 52-week results from SPROUT randomised control trial

Br J Dermatol 2025;193:1120–1127 Doi: 10.1093/bjd/ljaf305

Zhang W,

Zhang Z,

Paller et al. evaluated the long-term efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis through the 52-week Phase III SPROUT trial. The study assessed whether clinical responses were sustained after the placebo-controlled period and whether outcomes differed between treatment sequences.

Keywords:

Effect of apremilast on hand and whole-body MRI assessments of inflammation in patients with psoriatic arthritis (MOSAIC): a phase 4, multicentre, single-arm, open-label study

Lancet Rheumatol. 2024 Doi: 10.1016/S2665-9913(24)00232-7

Bubb MR,

Reddy J,

Zhou Z,

Østergaard et al. conducted a phase 4 multicentre, single-arm, open-label study to evaluate the effect of apremilast on MRI-assessed inflammation in PsA patients using PsAMRIS and MRI-WIPE. The study demonstrated that apremilast reduced inflammation in joints and entheses with no structural damage progression. The study also supports the use of MRI as an objective tool in PsA trials.